Items where Author is "Linassier, C."

Group by: Item Type | Uncontrolled Keywords | No Grouping

Kidney cancer Mammalian target of rapamycin (mTOR) Sequence Tyrosine kinase inhibitor

Number of items: 4.

Kidney cancer

Elaidi, R., Harbaoui, A., Beuselinck, B., Eymard, J..-C.., Bamias, A., De Guillebon, E., Porta, C., Vano, Y., Linassier, C., Debruyne, P. R., Gross-Goupil, M., Ravaud, A., Aitelhaj, M., Marret, G. and Oudard, S. (2014) Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Annals of Oncology, 26 (2). pp. 378-385. ISSN 0923-7534 (Print), 1569-8041 (Online) (doi:https://doi.org/10.1093/annonc/mdu552)

Mammalian target of rapamycin (mTOR)

Elaidi, R., Harbaoui, A., Beuselinck, B., Eymard, J..-C.., Bamias, A., De Guillebon, E., Porta, C., Vano, Y., Linassier, C., Debruyne, P. R., Gross-Goupil, M., Ravaud, A., Aitelhaj, M., Marret, G. and Oudard, S. (2014) Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Annals of Oncology, 26 (2). pp. 378-385. ISSN 0923-7534 (Print), 1569-8041 (Online) (doi:https://doi.org/10.1093/annonc/mdu552)

Sequence

Elaidi, R., Harbaoui, A., Beuselinck, B., Eymard, J..-C.., Bamias, A., De Guillebon, E., Porta, C., Vano, Y., Linassier, C., Debruyne, P. R., Gross-Goupil, M., Ravaud, A., Aitelhaj, M., Marret, G. and Oudard, S. (2014) Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Annals of Oncology, 26 (2). pp. 378-385. ISSN 0923-7534 (Print), 1569-8041 (Online) (doi:https://doi.org/10.1093/annonc/mdu552)

Tyrosine kinase inhibitor

Elaidi, R., Harbaoui, A., Beuselinck, B., Eymard, J..-C.., Bamias, A., De Guillebon, E., Porta, C., Vano, Y., Linassier, C., Debruyne, P. R., Gross-Goupil, M., Ravaud, A., Aitelhaj, M., Marret, G. and Oudard, S. (2014) Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Annals of Oncology, 26 (2). pp. 378-385. ISSN 0923-7534 (Print), 1569-8041 (Online) (doi:https://doi.org/10.1093/annonc/mdu552)

This list was generated on Fri Nov 22 01:36:54 2024 UTC.